-
June 8, 2021 Cybin Launches First Clinical Trial to Treat Frontline Workers Experiencing COVID-Related Distress With PsychedelicsA new first-of-its-kind psychedelic study will treat frontline workers experiencing distress related to COVID with...
-
June 8, 2021 Field Trip Health Begins Trading on TSE, Sets Sights on NasdaqPsychedelic lifestyle brand Field Trip Health is now trading on the Toronto Stock Exchange under...
-
June 8, 2021 What Is Psychedelic-Assisted Therapy? Here’s Everything You Need to KnowWhat is psychedelic-assisted therapy and does it work? Here's everything you need to know about...
-
June 7, 2021 GH Research Is Taking Psychedelic 5-MeO-DMT ‘Toad Venom’ PublicGH Research is taking its psychedelic 5-MeO-DMT public on the Nasdaq with an IPO valued...
-
June 7, 2021 AI Tech-Led Psychedelic Therapy Platform Nue Life Health Raises $3.3 MillionNue Life Health is a new therapy platform relying on AI and music as well...
-
June 4, 2021 Biotech Firm PsyBio Therapeutics Is Producing Psilocybin From BacteriaPsyBio Therapeutics is harvesting the psychedelic compound psilocybin from a strain of bacteria instead of...
-
June 4, 2021 Psychedelic Business Spotlight: June 4, 2021This week in psychedelic business: Mindset Pharma's new research, synthetic ibogaine, and the Western Hemisphere...
-
June 2, 2021 How a Psilocybin Retreat Changed Everything I Knew About PsychedelicsHere's how a legal psilocybin truffle retreat in the Netherlands changed this author's relationship with...
-
June 2, 2021 Cybin Taps First-of-Its-Kind Device to Study Psychedelic Effects of KetamineA new device may help Cybin better understand the psychedelic impact of the drug ketamine...
-
June 2, 2021 ‘PSY’ Becomes First U.S.-Listed Psychedelic ETFDefiance Next Gen Altered Experience ETF began trading Friday on the New York Stock Exchange...
